COMP <GO>
DNTH vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
Dianthus Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: DNTH 2
— JNJ 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $82.38 (-0.39%) • MKT CAP: $4.63B
roic
-30.70%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DNTH VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DNTH | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -30.70% | 25.50% | -56.20 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.79% | 2.97% | -5.76 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 6.00% | -71.00 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | DNTH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.8 | 60.4 | -13.56 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.08 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.0x | 23.0x | -3.00 | DNTH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.63B | $662.49B | -$657.87B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DNTH REV | JNJ REV | DNTH GROSS % | JNJ GROSS % | DNTH FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.0M | $94.19B | 44.0% | 67.9% | -$129.2M | $19.70B |
| FY 2024 | $6.2M | $88.82B | 44.0% | 69.1% | -$78.5M | $19.84B |
| FY 2023 | $2.8M | $85.16B | 44.0% | 44.0% | -$37.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DNTH // BETA 1.08
JNJ // BETA 1.08